Given the high PD-L1 expression found in BRAF V600E mutant tumors and the very high TMB levels in non-BRAF V600E mutant tumors, ICI/chemotherapy may be a highly effective choice as first-line therapy, with the option to provide approved targeted therapies for BRAF V600E NSCLC patients after progression. This evidence concerns the gene BRAF and non-small cell lung carcinoma.